180698-19-5

Basic information

• Product Name: 1-(4-BIPHENYLYL)-PIPERAZINE
• Synonyms: 4-(Piperazin-1-yl)biphenyl;1-(4-Phenylphenyl)piperazine;RARECHEM AH CK 0038;AKOS BB-5571;1-(4-BIPHENYLYL)-PIPERAZINE;1-BIPHENYL-4-YL-PIPERAZINE;1-(1,1'-biphenyl-4-yl)piperazine;1-(4-BIPHENYLYL)-PIPERAZINE >98%
• CAS NO: 180698-19-5
• Molecular Formula: C₁₆H₁₈N₂
• Molecular Weight: 238.33
• Product Categories: piperazines
• Mol File: 180698-19-5.mol
• Article Data: 8

Chemical Properties

• Melting Point: 142-143°C
• Boiling Point: 422 °C at 760 mmHg
• Flash Point: 192.2 °C
• Appearance: /
• Density: 1.068 g/cm³
• Vapor Pressure: 2.5E-07mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 1-(4-BIPHENYLYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-BIPHENYLYL)-PIPERAZINE(180698-19-5)
• EPA Substance Registry System: 1-(4-BIPHENYLYL)-PIPERAZINE(180698-19-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 180698-19-5(Hazardous Substances Data)

Usage

General Description

1-(4-biphenylyl)-piperazine is a chemical compound that belongs to the class of piperazine derivatives. It is a heterocyclic organic compound with a piperazine ring and a biphenyl moiety. 1-(4-BIPHENYLYL)-PIPERAZINE is commonly used as a starting material in organic synthesis and pharmaceutical research. It has been identified as a potential central nervous system depressant and is being investigated for its potential use in the development of new medications for the treatment of various neurological and psychiatric disorders. 1-(4-biphenylyl)-piperazine is also known to possess some level of serotonin receptor activity, which makes it a subject of interest in the development of antidepressant and antipsychotic medications.

InChI:InChI=1/C16H18N2/c1-2-4-14(5-3-1)15-6-8-16(9-7-15)18-12-10-17-11-13-18/h1-9,17H,10-13H2

Upstream product

• 4974-58-7 4-biphenylglyoxal 
• 107-15-3 ethylenediamine 
• 92-91-1 biphenyl-4-acetaldehyde 
• 92-52-4 biphenyl 
• 140681-55-6 Selectfluor 
• 92-54-6 4-phenyl-1-piperazine 
• 96530-59-5 1-(piperazin-1-yl)-4-iodobenzene 
• 151978-66-4 tert-butyl 4-(4-iodophenyl)tetrahydro-1(2H)-pyrazinecarboxylate 
• 681482-18-8 t-butyl 4-([1,1′-biphenyl]-4-yl)piperazine-1-carboxylate 
• 327030-32-0 1-benzyl-4-biphenyl-4-yl-piperazine 
• 110-85-0 piperazine 
• 92-66-0 4-bromo-1,1'-biphenyl 

Downstream Products

• 331767-13-6 9-[4-(4-biphenyl-4-yl-piperazin-1-yl)-butyl]-9H-fluorene-9-carboxylic acid-(2,2,2-trifluoroethyl)-amide 
• 886770-41-8 4-(N-Boc-piperazin-3-yl)biphenyl 
• 1026084-40-1 D-264 
• 1563175-22-3 1-([1,1′-biphenyl]-4-yl)-4-(2-((tert-butyldimethylsilyl)oxy)ethyl)piperazine 
• 1610998-23-6 1-[5-(benzyloxy)-1H-indol-3-yl]-2-[4-(biphenyl-4-yl)piperazin-1-yl]ethane-1,2-dione 
• 1608157-06-7 N⁵-(2-(4-([1,1’-biphenyl]-4-yl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]trizaine-5,7-diamine 
• 937664-54-5 2-(4-(biphenyl-4-yl)piperazin-1-yl)ethanamine 
• 1608156-87-1 2-(2-(4-([1,1’-biphenyl]-4-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione 
• 1580436-62-9 quinuclidin-3-yl 4-([1,1'-biphenyl]-4-yl)piperazine-1-carboxylate 
• 1580436-57-2 4-([1,1'-biphenyl]-4-yl)-N-(3-methylquinuclidin-3-yl)piperazine-1-carboxamide 
• 1580436-61-8 (4-([1,1'-biphenyl]-4-yl)piperazin-1-yl)(1,4-diazabicyclo[3.2.2]nonan-4-yl)methanone 
• 1563175-17-6 N6-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N6-propyl-5,6,7,8-tetrahydroquinazoline-2,6-diamine 
• 1563175-15-4 4-((2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)(propyl)amino)cyclohexanone 
• 1563175-08-5 N-(2-(4-([1,1′-biphenyl]-4-yl)piperazin-1-yl)ethyl)-N-propyl-1,4-dioxaspiro[4.5]decan-8-amine 

Relevant articles and documents

Biphenyl substituted piperazine derivative synthesis method

The invention discloses a biphenyl substituted piperazine derivative 4-(N-Boc-piperazine-3-yl)biphenyl synthesis method. 4-acetyl biphenyl is taken as a starting material and subjected to oxidation, cyclization and Boc addition to obtain a target product. A biphenyl substituted piperazine derivative which is a compound is an important medical intermediate.

Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson's disease

Parkinson's disease (PD) is one of the major debilitating neurodegenerative disorders affecting millions of people worldwide. Progressive loss of dopamine neurons resulting in development of motor dysfunction and other related non-motor symptoms is the hallmark of PD. Previously, we have reported on the neuroprotective property of a potent D3 preferring agonist D-264. In our goal to increase the bioavailability of D-264 in the brain, we have synthesized a modified cysteine based prodrug of D-264 and evaluated its potential in crossing the blood-brain barrier. Herein, we report the synthesis of a novel modified cysteine conjugated prodrug of potent neuroprotective D3 preferring agonist D-264 and systematic evaluation of the hydrolysis pattern of the prodrug to yield D-264 at different time intervals in rat plasma and brain homogenates using HPLC analysis. Furthermore, we have also performed in vivo experiments with the prodrug to evaluate its enhanced brain penetration ability.

Further delineation of hydrophobic binding sites in dopamine D 2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5, 6,7,8-tetrahydro-naphthalen-2-ol

Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro- naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (Ki), as measured with tritiated spiperone and HEK-293 cells expressing either D2 or D3 receptors. Functional activity of selected compounds was assessed with the GTPγS binding assay. Compound 8d was the most selective for the D3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D2/D3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D2/D3 (ratio of EC50): 105 and 202, respectively) for the D3 receptor and both compounds were more selective compared to the reference drug ropinirole (D2/D3 (ratio of EC50): 29.5).